HCMHutchmedFinished
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 61 (final count)
- Started
- Nov 5, 2024
- Main results expected
- May 23, 2026
- Fully finished
- May 23, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS)
Measured over: Up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06601504 · record last updated 2026-09-24 · checked 2026-11-09 15:36 UTC